Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus (Adv. Sci. 19/2024).

CRISPR Gene TherapyIn article number 2308095, Wei Li, Fei Teng, and colleagues introduce a hypercompact CRISPR‐Cas12f1 system characterized by enhanced gene editing capabilities and minimal off‐target effects. Applied to the treatment of inherited retinal diseases, this system shows significant therapeutic outcomes, highlighting its substantial promise for gene therapy applications..By Tongtong Cui; Bingyu Cai; Yao Tian; Xin Liu; Chen Liang; Qingqin Gao; Bojin Li; Yali Ding; Rongqi Li; Qi Zhou; Wei Li and Fei TengReported by Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author [Extracted from the article]